"Abbreviated" Biologics Applications: The Reality of Providing Biosimilar Products


The newly enacted follow-on Biologics legislation provides a regulatory pathway for approving biosimilar and interchangeable biologic drugs, along with tectonically shifting the patent clearance considerations compared to the Hatch-Waxman regime for small molecule pharmaceutical generics.

Read the full article.

Email Disclaimer